Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipe…
An institutional-grade, numbers-driven thesis on IRON — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Disc Medicine, Inc. (IRON) 56/100 with a 12-month base-case forecast of $101.60 — +31.2% versus the current price of $77.44. Disc Medicine, Inc. trades at $77.44 in the Healthcare sector, with a market capitalisation of $2.97B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for IRON is $101.60, implying +31.2% versus the current price. The model's 12-month scenario range runs from $67.41 (bear) to $123.93 (bull), with a base case of $90.78.
On the fundamentals, Disc Medicine shows a P/E of -11.7, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks IRON's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
IRON currently carries a TradersQuant composite score of 56/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $101.60 implies +31.2% from $77.44. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for IRON is $101.60, about +31.2% versus the latest price of $77.44. Consensus is based on 11 analysts.
TradersQuant's 12-month model forecast for IRON is a base case of $90.78, ranging from $67.41 (bear) to $123.93 (bull), an expected return of +17.2%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for IRON over the next 12 months is $90.78 in the base case (bear $67.41, bull $123.93), versus today's price of $77.44. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for IRON — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates IRON's fair value at $101.60, implying +31.2% of expected upside versus the current price.
Disc Medicine does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
